Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
It is expected to be licensed by the FDA in mid-2026
#Lilly #HanmiPharmaceutical #GLP2 #Sonefpeglutide #ShortBowelSyndrome #Gastroenterology #RareDisease #Biotech #DrugDevelopment #Pharma #HealthcareInnovation #Biologics #LicensingDeal #PrecisionMedicine Eli Lilly is making a strategic bet on nextgeneration gut biology, licensing Hanmis longacting GLP2 analog sonefpeglutide in a deal worth up to $1.26B
MYTH #4: Botox overrides triggers
Pancreatitis (NG104) Recommendations
Positive reviewers frequently mention responsive care teams, fast delivery and gratitude for savings on medications thanks to their promotions
US$ 23.04
US$ 29.94
US$ 27.74
US$ 21.69
US$ 26.48
US$ 28.62
